By reducing estrogen levels, aromatase inhibitors effectively control cancer growth and have demonstrated significant efficacy in lowering recurrence rates and improving survival, making them a key component of standard adjuvant therapy [8]. This evidence concerns the gene CYP19A1 and cancer.